Association between plasma IL-6, the IL6 -174G>C gene variant and the metabolic syndrome in type 2 diabetes mellitus

Molecular Genetics and Metabolism

Volumn 90, Issue 4, 2007, Pages 422-428

  Stephens, Jeffrey W ^a   Hurel, Steven J ^b   Lowe, Gordon D O ^c   Rumley, Ann ^c   Humphries, Steve E ^d  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Diabetes; Gene; Inflammation; Interleukin 6; Metabolic syndrome

Indexed keywords

INTERLEUKIN 6;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BODY MASS; CAUCASIAN; DISEASE ASSOCIATION; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL;

EID: 33947609334     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2006.10.004     Document Type: Article

References (35)

1. Papanicolaou D.A., Wilder R.L., Manolagas S.C., and Chrousos G.P. The pathophysiologic roles of interleukin-6 in human disease. Ann. Intern. Med. 128 (1998) 127-137
2. Pradhan A.D., Manson J.E., Rifai N., Buring J.E., and Ridker P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286 (2001) 327-334
3. Heinrich P.C., Castell J.V., and Andus T. Interleukin-6 and the acute phase response. Biochem. J. 265 (1990) 621-636
4. Ridker P.M., Rifai N., Stampfer M.J., and Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101 (2000) 1767-1772
5. Sattar P.C., and Petrie Jr. N. Type 2 diabetes as an inflammatory disorder. Br. J. Diabetes Vasc. Dis. 3 (2003) 36-41
6. Freeman D.J., Norrie J., Caslake M.J., Gaw A., Ford I., Lowe G.D., O'Reilly D.S., Packard C.J., and Sattar N. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 51 (2002) 1596-1600
7. Hotamisligil G.S., Shargill N.S., and Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259 (1993) 87-91
8. Hotamisligil G.S., and Spiegelman B.M. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 43 (1994) 1271-1278
9. Lagathu C., Bastard J.P., Auclair M., Maachi M., Capeau J., and Caron M. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem. Biophys. Res. Commun. 311 (2003) 372-379
10. Humphries S.E., Talmud P.J., Hawe E., Bolla M., Day I.N., and Miller G.J. Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study. Lancet 358 (2001) 115-119
11. Fishman D., Faulds G., Jeffery R., Mohamed-Ali V., Yudkin J.S., Humphries S., and Woo P. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J. Clin. Invest. 102 (1998) 1369-1376
12. Hulkkonen J., Pertovaara M., Antonen J., Pasternack A., and Hurme M. Elevated interleukin-6 plasma levels are regulated by the promoter region polymorphism of the IL6 gene in primary Sjogren's syndrome and correlate with the clinical manifestations of the disease. Rheumatology (Oxford) 40 (2001) 656-661
13. Terry C.F., Loukaci V., and Green F.R. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J. Biol. Chem. 275 (2000) 18138-18144
14. Brull D.J., Montgomery H.E., Sanders J., Dhamrait S., Luong L., Rumley A., Lowe G.D., and Humphries S.E. Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1458-1463
15. Jones K.G., Brull D.J., Brown L.C., Sian M., Greenhalgh R.M., Humphries S.E., and Powell J.T. Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms. Circulation 103 (2001) 2260-2265
16. Qi L., van Dam R.M., Meigs J.B., Manson J.E., Hunter D., and Hu F.B. Genetic variation in IL6 gene and type 2 diabetes: tagging-SNP haplotype analysis in large-scale case-control study and meta-analysis. Hum. Mol. Genet. 15 (2006) 1914-1920
17. Kubaszek A., Pihlajamaki J., Punnonen K., Karhapaa P., Vauhkonen I., and Laakso M. The C-174G promoter polymorphism of the IL-6 gene affects energy expenditure and insulin sensitivity. Diabetes 52 (2003) 558-561
18. Berthier M.T., Houde A., Cote M., Paradis A.M., Mauriege P., Bergeron J., Gaudet D., Despres J.P., and Vohl M.C. Impact of adiponectin gene polymorphisms on plasma lipoprotein and adiponectin concentrations of viscerally obese men. J. Lipid Res. 46 (2005) 237-244
19. Stephens J.W., Hurel S.J., Cooper J.A., Acharya J., Miller G.J., and Humphries S.E. A common functional variant in the interleukin-6 gene is associated with increased body mass index in subjects with type 2 diabetes mellitus. Mol. Genet. Metab. 82 (2004) 180-186
20. Klipstein-Grobusch K., Mohlig M., Spranger J., Hoffmann K., Rodrigues F.U., Sharma A.M., Klaus S., Pfeiffer A.F., and Boeing H. Interleukin-6 g-174G>C promoter polymorphism is associated with obesity in the EPIC-Potsdam Study. Obesity (Silver Spring) 14 (2006) 14-18
21. Walch K., Grimm C., Zeillinger R., Huber J.C., Nagele F., and Hefler L.A. A common interleukin-6 gene promoter polymorphism influences the clinical characteristics of women with polycystic ovary syndrome. Fertil. Steril. 81 (2004) 1638-1641
22. Vozarova B., Fernandez-Real J.M., Knowler W.C., Gallart L., Hanson R.L., Gruber J.D., Ricart W., Vendrell J., Richart C., Tataranni P.A., and Wolford J.K. The interleukin-6 (-174) G/C promoter polymorphism is associated with type-2 diabetes mellitus in Native Americans and Caucasians. Hum. Genet. 112 (2003) 409-413
23. Illig T., Bongardt F., Schopfer A., Muller-Scholze S., Rathmann W., Koenig W., Thorand B., Vollmert C., Holle R., Kolb H., and Herder C. Significant association of the interleukin-6 gene polymorphisms C-174G and A-598G with type 2 diabetes. J. Clin. Endocrinol. Metab. 89 (2004) 5053-5058
24. Mohlig M., Boeing H., Spranger J., Osterhoff M., Kroke A., Fisher E., Bergmann M.M., Ristow M., Hoffmann K., and Pfeiffer A.F. Body mass index and C-174G interleukin-6 promoter polymorphism interact in predicting type 2 diabetes. J. Clin. Endocrinol. Metab 89 (2004) 1885-1890
25. Huth C., Heid I.M., Vollmert C., Gieger C., Grallert H., Wolford J.K., Langer B., Thorand B., Klopp N., Hamid Y.H., Pedersen O., Hansen T., Lyssenko V., Groop L., Meisinger C., Doring A., Lowel H., Lieb W., Hengstenberg C., Rathmann W., Martin S., Stephens J.W., Ireland H., Mather H., Miller G.J., Stringham H.M., Boehnke M., Tuomilehto J., Boeing H., Mohlig M., Spranger J., Pfeiffer A., Wernstedt I., Niklason A., Lopez-Bermejo A., Fernandez-Real J.M., Hanson R.L., Gallart L., Vendrell J., Tsiavou A., Hatziagelaki E., Humphries S.E., Wichmann H.E., Herder C., and Illig T. IL6 gene promoter polymorphisms and type 2 diabetes: joint analysis of individual participants' data from 21 studies. Diabetes 55 (2006) 2915-2921
26. Stephens J.W., Hurel S.J., Acharya J., and Humphries S.E. An interaction between the interleukin-6 -174G>C gene variant and urinary protein excretion influences plasma oxidative stress in subjects with type 2 diabetes. Cardiovasc. Diabetol. 3 (2004) 2
27. Stephens J.W., Dhamrait S.S., Cooper J.A., Acharya J., Miller G.J., Hurel S.J., and Humphries S.E. The D allele of the ACE I/D common gene variant is associated with Type 2 diabetes mellitus in Caucasian subjects. Mol. Genet. Metab. 84 (2005) 83-89
28. Alberti K.G., and Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15 (1998) 539-553
29. Stephens J.W., and Humphries S.E. The molecular genetics of cardiovascular disease: clinical implications. J. Intern. Med. 253 (2003) 120-127
30. World Health Organisation.Definition, Diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Geneva: World Health Organization. (1999).
31. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497.
32. Alberti K.G., Zimmet P., and Shaw J. Metabolic syndrome-a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet. Med. 23 (2006) 469-480
33. Bastard J.P., Maachi M., Van Nhieu J.T., Jardel C., Bruckert E., Grimaldi A., Robert J.J., Capeau J., and Hainque B. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J. Clin. Endocrinol. Metab. 87 (2002) 2084-2089
34. Clarke D., and Mohamed-Ali V. The role of interleukin-6 in adipogenesis. ENDO (2000) 1213 (Abstract)
35. Rotter V., Nagaev I., and Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and TNFalpha, overexpressed in human fat cells from insulin-resistant subjects. J. Biol. Chem. (2003)